

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

THE CLINICAL TRIAL APPROVAL FOR SIM0609

(CDH17 ANTIBODY-DRUG CONJUGATE)

ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that, on September 5, 2025, SIM0609, a CDH17 Antibody-Drug Conjugate (ADC) which is an anti-tumor drug candidate independently developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (國家藥品監督管理局) of China, which is intended for commencing the clinical trial for advanced solid tumors.

ABOUT SIM0609

SIM0609 is a novel CDH17-targeting ADC, consisting of a humanized monoclonal antibody conjugated to the Group’s proprietary novel topoisomerase I (TOP-I) inhibitor via a new hydrophilic cleavable linker. CDH17 is highly expressed in various cancers, including gastric cancer, colorectal cancer, pancreatic cancer and etc, suggesting that CDH17 is an attractive therapeutic target for treatment of advanced solid tumors, particularly for gastrointestinal carcinomas.

ABOUT THE COMPANY

The Company is an innovation and R&D-driven pharmaceutical company and has established a “State Key Laboratory of Neurology and Oncology Drug Development”. The Company focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of “for patients, for life”. Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, September 8, 2025

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. TANG Renhong, Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.